Literature DB >> 10767320

Structural features of normal and mutant human lysosomal glycoside hydrolases deduced from bioinformatics analysis.

P Durand1, S Fabrega, B Henrissat, J P Mornon, P Lehn.   

Abstract

Lysosomal storage diseases are due to inherited deficiencies in various enzymes involved in basic metabolic processes. As with other genetic diseases, accurate structure data for these enzymatic proteins should help in better understanding the molecular effects of mutations identified in patients with the corresponding lysosomal diseases; however, no such three-dimensional (3D) structure data are available for many lysosomal enzymes. Thus, we herein intend to illustrate for an audience of molecular geneticists how structure information can nonetheless be obtained via a bioinformatics approach in the case of five human lysosomal glycoside hydrolases. Indeed, using the two-dimensional hydrophobic cluster analysis method to decipher the sequence information available in data banks for the large group of glycoside hydrolases (clan GH-A) to which these human lysosomal enzymes belong, we could deduce structure predictions for their catalytic domains and propose explanations for the molecular effects of mutations described in patients. In addition, in the case of human beta-glucuronidase for which experimental 3D data have been reported, we also show here that bioinformatics methods relying on the available 3D structure information can be used to obtain further insights into the effects of various mutations described in patients with Sly disease. In a broader perspective, our work stresses that, in the context of a rapid increase in protein sequence information through genome sequencing, bioinformatics approaches might be highly useful for generating structure-function predictions based on sequence-structure interrelationships.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10767320     DOI: 10.1093/hmg/9.6.967

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  5 in total

1.  Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease.

Authors:  Anu R Sawkar; Wei-Chieh Cheng; Ernest Beutler; Chi-Huey Wong; William E Balch; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-14       Impact factor: 11.205

2.  Beta-galactosidase deficiency: an approach to chaperone therapy.

Authors:  Yoshiyuki Suzuki
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

3.  Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis.

Authors:  Junichiro Matsuda; Osamu Suzuki; Akihiro Oshima; Yoshie Yamamoto; Akira Noguchi; Kazuhiro Takimoto; Masayuki Itoh; Yuji Matsuzaki; Yosuke Yasuda; Seiichiro Ogawa; Yuko Sakata; Eiji Nanba; Katsumi Higaki; Yoshimi Ogawa; Lika Tominaga; Kousaku Ohno; Hiroyuki Iwasaki; Hiroshi Watanabe; Roscoe O Brady; Yoshiyuki Suzuki
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

Review 4.  Pharmacological chaperoning: a primer on mechanism and pharmacology.

Authors:  Nancy J Leidenheimer; Katelyn G Ryder
Journal:  Pharmacol Res       Date:  2014-02-14       Impact factor: 7.658

5.  A rapid and sensitive method for measuring N-acetylglucosaminidase activity in cultured cells.

Authors:  Victor Mauri; Parisa Lotfi; Laura Segatori; Marco Sardiello
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.